Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity.
Substituted azaquinazolinones were identified as antagonists of the GHSr-1A receptor for the treatment of type II diabetes and obesity. Optimisation for potency and LogD lead to the identification of orally bioavailable, potent antagonists with improved selectivity over hERG.